Literature DB >> 2044642

Fibrates and triglyceride metabolism.

P Schwandt1.   

Abstract

Some mechanisms of the triglyceride-lowering effects of fibrates in patients with hypertriglyceridemia are reviewed. One main effect of the fibrates is the stimulation of lipoprotein lipase activities in plasma as well as in adipose tissue. According to this increase in the degradational activity VLDL catabolism is stimulated, as has been demonstrated for VLDL apo B and VLDL triglycerides. In addition, the composition of hypertriglyceridemic LDL is reverted towards normal. Furthermore, the increased degradation via the nonreceptor pathway is decreased by fibrate treatment, thus lowering the atherogenic potential of triglyceride-rich lipoproteins. But additionally the degree of postprandial hypertriglyceridemia is lowered by fibrates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044642

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

Review 1.  Enzymes involved in triglyceride hydrolysis.

Authors:  M R Taskinen; T Kuusi
Journal:  Baillieres Clin Endocrinol Metab       Date:  1987-08

2.  Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects.

Authors:  C J Packard; R J Clegg; M H Dominiczak; A R Lorimer; J Shepherd
Journal:  J Lipid Res       Date:  1986-09       Impact factor: 5.922

3.  Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.

Authors:  J Shepherd; C J Packard; J M Stewart; R F Atmeh; R S Clark; D E Boag; K Carr; A R Lorimer; D Ballantyne; H G Morgan
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

4.  Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.

Authors:  S Eisenberg; D Gavish; Y Oschry; M Fainaru; R J Deckelbaum
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

5.  Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.

Authors:  M S Weintraub; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

6.  Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.

Authors:  Y A Kesäniemi; S M Grundy
Journal:  JAMA       Date:  1984-05-04       Impact factor: 56.272

7.  Mechanism of action of gemfibrozil on lipoprotein metabolism.

Authors:  K Saku; P S Gartside; B A Hynd; M L Kashyap
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

  7 in total
  1 in total

Review 1.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.